Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 2
2001 3
2003 6
2004 4
2005 6
2006 5
2007 12
2008 9
2009 16
2010 5
2011 19
2012 20
2013 27
2014 13
2015 18
2016 13
2017 26
2018 17
2019 21
2020 17
2021 25
2022 19
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: havrilesky l. J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584549 Clinical Trial.
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Fader AN, et al. Among authors: havrilesky l. Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29. Clin Cancer Res. 2020. PMID: 32601075 Free PMC article. Clinical Trial.
Benefits and Harms of Breast Cancer Screening: A Systematic Review.
Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, Davidson B, Mongtomery RC, Crowley MJ, McCrory DC, Kendrick A, Sanders GD. Myers ER, et al. Among authors: havrilesky lj. JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183. JAMA. 2015. PMID: 26501537 Review.
The Clinical Trial Conundrum for Gynecologic Cancers.
Havrilesky LJ, Moss HA. Havrilesky LJ, et al. Obstet Gynecol. 2023 Sep 1;142(3):457-458. doi: 10.1097/AOG.0000000000005307. Epub 2023 Aug 3. Obstet Gynecol. 2023. PMID: 37548377 No abstract available.
In reply.
Havrilesky LJ, Myers ER, Thomas WL. Havrilesky LJ, et al. Obstet Gynecol. 2013 Nov;122(5):1114. doi: 10.1097/01.AOG.0000435077.65209.72. Obstet Gynecol. 2013. PMID: 24150023 No abstract available.
Epithelial ovarian cancer.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL; National Comprehensive Cancer Network. Morgan RJ Jr, et al. Among authors: havrilesky lj. J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. doi: 10.6004/jnccn.2011.0008. J Natl Compr Canc Netw. 2011. PMID: 21233246 No abstract available.
Is Intraperitoneal Chemotherapy Dead?
Secord AA, Havrilesky LJ. Secord AA, et al. Among authors: havrilesky lj. Obstet Gynecol. 2016 Jun;127(6):983-984. doi: 10.1097/AOG.0000000000001461. Obstet Gynecol. 2016. PMID: 27159765 No abstract available.
286 results